65,437 trials
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
Post-Traumatic Headache
Primary: Change From Baseline in Headache Frequency — 16.4; 18.5; -9.2; -7.4 headaches per month
Access to Health Care
Primary: User Evaluation Survey
Prurigo Nodularis
Primary: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16…
Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity
Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants
Asthma
Primary: Percentage of Participants Who Achieved Fractional Exhaled Nitric Oxide (FeNO) Less Than (<) 25 Parts Per Billion (Ppb) at Week 24 — 56.9; 10.8 percentage of…
Extensive-stage Small-cell Lung Cancer
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1 — 2200; 2598; 2878; 2675 h*ng/mL
Stigma, Social · Substance Use
Primary: Change in Stigma Resistance Scale (SRS) Score — 6.28 score on a scale
HIV Infections · HIV/AIDS · Neisseria Gonorrheae Infection
Primary: Incidence of N. Gonorrhoeae, C. Trachomatis, or Early Syphilis Infection by Laboratory-based Diagnosis — 25.1; 29.0 Events per 100 person-years
Autistic Disorder · Autism Spectrum Disorder · Child Development Disorders, Pervasive
Primary: Parts 1, 2 and 3: Percentage of Participants With Adverse Events — 2; 2; 2; 4 Participants
Thoracoabdominal Aortic Aneurysm · Pararenal Aortic Aneurysm
Primary: Number of Participants With Major Adverse Events (MAE) Within 30 Days Postoperative — 1 participants
Thrombosis · Hemolysis
Primary: Area Under the Curve for Adenosine Diphosphate (ADP) — 50; 20; 50; 6 omhs x seconds (AUC)
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Facioscapulohumeral Muscular Dystrophy (FSHD)
Primary: Change From Baseline in Double Homeobox 4 (DUX4) Activity in Affected Skeletal Muscle — 0.8292; 0.4008 Delta threshold cycle (Ct) — p=0.5621
Immune Thrombocytopenia
Primary: Platelet Response — 12; 14; 4 Participants